Detail akcie Ventyx Biosciens Rg online

Business Summary: Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Ventyx Biosciences Inc revenues was not reported. Net loss decreased 27% to $77.3M. Lower net loss reflects Research and development - Balancing decrease of 33% to $56.3M (expense), Stock-based Compensation in SGA decrease of 21% to $7.6M (expense), Stock-based Compensation in R&D decrease of 19% to $6.6M (expense).